London: The U.K. government reached an agreement with pharmaceutical giants Sanofi and Glaxosmithkline for a supply of up to 60 million doses of a potential Covid-19 vaccine.
A vaccine candidate is being developed by the two companies. Clinical trials are expected to start in September and regulatory approval could be achieved by the first half of 2021 if the data are positive, Sanofi said in a statement on Wednesday.
More than 100 vaccine candidates are currently being developed, with 25 of them in clinical trials as of July 28, according to the World Health Organization.
The U.K. has also signed supply deals for other vaccine candidates that are being studied. That includes 100 million doses of University of Oxford’s potential vaccine being developed by AstraZeneca.
